Title - Vitiligo etiology – facts, theories and myths – based on a case report.
Hepatitis C Treatment in Corrections: New Medicine, New Challenges Spencer Epps, MD, MBA, Medical Director Delaware Department of Correction James Welch,
Psychiatric treatment considerations with direct acting antivirals in hepatitis C
VOGT-KOYANAGI-HARADA DISEASE AHMED M. ABU EL-ASRAR, MD, PhD Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
VOGT-KOYANAGI-HARADA DISEASE
Quali sono i limiti dell’attuale terapia Terapia dell’epatite C tra passato e futuro Alessandro Grasso S.C. Medicina Interna e Gastroenterologia Osp. San.
Module 7: Managing side effects and optimising treatment strategies.
SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials Analysis of Resistance Associated Variants by HCV Genotype 1 subtypes 1a and.
SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials
